Trial Profile
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Nov 2019
Price :
$35
*
At a glance
- Drugs Onatasertib (Primary)
- Indications Liver cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Pharmacokinetics
- Acronyms AME/FE
- 23 Jul 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 12 Jun 2012 New trial record